LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Search

CytoSorbents Corp

Closed

SectorHealthcare

1.12 0.9

Overview

Share price change

24h

Current

Min

1.12

Max

1.15

Key metrics

By Trading Economics

Income

3.4M

1.9M

Sales

890K

9.6M

Profit margin

20.245

Employees

149

EBITDA

-3.1M

-3.6M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-13.79% downside

Dividends

By Dow Jones

Next Earnings

6 lis 2025

Market Stats

By TradingEconomics

Market Cap

18M

75M

Previous open

0.22

Previous close

1.12

News Sentiment

By Acuity

38%

62%

113 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

CytoSorbents Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 sie 2025, 16:11 UTC

Major Market Movers

Health Insurers Climb as Berkshire Hathaway Takes UnitedHealth Stake

15 sie 2025, 22:22 UTC

Market Talk

Global Equities Roundup: Market Talk

15 sie 2025, 22:22 UTC

Market Talk

Target Is Falling Behind Its Peers -- Market Talk

15 sie 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 sie 2025, 20:33 UTC

Market Talk

U.S. Treasury Yields Close the Week Little Changed -- Market Talk

15 sie 2025, 20:25 UTC

Earnings
Acquisitions, Mergers, Takeovers

This Meatpacker Stock Is a Quality Buy at a Discount Price -- Barrons.com

15 sie 2025, 20:24 UTC

Earnings
Acquisitions, Mergers, Takeovers

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15 sie 2025, 20:18 UTC

Earnings

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15 sie 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Settles Higher, But Down on Week -- Market Talk

15 sie 2025, 19:12 UTC

Market Talk

Oil Futures Settle Lower Ahead of U.S.-Russia Summit -- Market Talk

15 sie 2025, 18:32 UTC

Market Talk

Coffee Futures Surge on New Brazilian Frost -- Market Talk

15 sie 2025, 17:33 UTC

Market Talk

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

15 sie 2025, 17:23 UTC

Market Talk
Earnings

Deere's Earnings Appear to Be Troughing -- Market Talk

15 sie 2025, 16:27 UTC

Earnings

Tariffs Have Rocked e.l.f. Beauty Shares. Why the Fundamentals Still Look Alluring. -- Barrons.com

15 sie 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 sie 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15 sie 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15 sie 2025, 16:05 UTC

Acquisitions, Mergers, Takeovers

Intel's Move Toward Nationalization Won't Work -- at Least for the Long Haul -- Heard on the Street -- WSJ

15 sie 2025, 15:52 UTC

Acquisitions, Mergers, Takeovers

What Applied Materials' Poor Outlook Means for Chip Stocks -- Barrons.com

15 sie 2025, 15:36 UTC

Market Talk

Base Metal Prices Mixed; Copper Gains as Focus Shifts to Fundamentals -- Market Talk

15 sie 2025, 15:29 UTC

Earnings

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15 sie 2025, 15:29 UTC

Acquisitions, Mergers, Takeovers

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15 sie 2025, 15:28 UTC

Earnings

JD.com Stock Rises After Earnings Beat. Why Investors Are Relieved. -- Barrons.com

15 sie 2025, 15:24 UTC

Market Talk

Gold Futures Tick Higher But Remain Broadly Rangebound -- Market Talk

15 sie 2025, 15:08 UTC

Market Talk

Applied Materials Is Losing Share in Chips Business -- Market Talk

15 sie 2025, 14:38 UTC

Acquisitions, Mergers, Takeovers

African Rainbow Minerals to Own 19.9% of Surge Copper Shares

15 sie 2025, 14:37 UTC

Acquisitions, Mergers, Takeovers

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares for C$4.51M

15 sie 2025, 14:37 UTC

Acquisitions, Mergers, Takeovers

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares at C$0.175 Each

15 sie 2025, 14:36 UTC

Acquisitions, Mergers, Takeovers

African Rainbow Minerals to Acquire Shares of Surge Copper Corp.

15 sie 2025, 14:33 UTC

Acquisitions, Mergers, Takeovers

A Trump Intel Stake Could Make National Security the New 'Too Big to Fail' -- Barrons.com

Peer Comparison

Price change

CytoSorbents Corp Forecast

Price Target

By TipRanks

-13.79% downside

12 Months Forecast

Average 1 USD  -13.79%

High 1 USD

Low 1 USD

Based on 2 Wall Street analysts offering 12 month price targets forCytoSorbents Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

2 ratings

0

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

0.705 / 0.771Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

113 / 374 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.